Fairway Consulting Group Appoints VP of Executive Search
September 20, 2024 – Executive search firm Fairway Consulting Group has expanded with the addition of Brennan Clark as vice president of executive search. “As we further expand our business globally, we are excited to welcome Brennan to our leadership team,” said Dan Gold, president of Fairway Consulting Group. “Our clients will benefit from his unique experience and insights.”
Mr. Brennan brings over 15 years of experience in building and leading high-performing, diverse teams. Most recently, he served as a talent acquisition and candidate experience leader at Pfizer, following its acquisition of Seagen. Mr. Brennan played a pivotal role at Seagen, helping to grow it from approximately 500 employees and a $6 billion market capitalization to nearly 4,000 employees and $43 billion respectively. Under his leadership, his team facilitated more than 2,000 hires prior to the acquisition. Earlier in his career, Mr. Brennan gained valuable experience with seven years in staffing and executive search, establishing a track record for delivering impactful HR and recruitment strategies.
“I have always been passionate about delivering a powerful candidate experience, and making quality hires in the life sciences space,” said Mr. Brennan. “I look forward to working with Fairway’s clients and helping to make a positive impact on their business.”
Based in New York, Fairway Consulting Group is an executive search firm for the life science industry. The firm, which has been in business for more than 20 years, has executed more than 1,000 searches. Its recruiting professionals focus on senior commercial operations and R&D roles.
Fairway Consulting Group was recently named as a Top 40 Life Sciences Executive Search Firm by Hunt Scanlon Media. “We are honored to be recognized as a leader in our industry by Hunt Scanlon,” said Mr. Gold. “Over the past 25 years, Fairway has built a distinguished reputation and results for our clients. We are committed to partnering with executive teams to find high impact talent, and are proud to say 85 percent of our searches are for returning clients.”
Life Sciences Sector
While the challenges facing life sciences worldwide are vast and varied, clear trends uncovered in three key economies indicate that medical fields are undergoing massive changes—changes that will require brave, ethical leadership, according to a recent report from Signium. “The life sciences industry is no stranger to controversy and conflicting opinions, and as the world continues to change at a pace that’s difficult to match, leaders find themselves confronted with extraordinary opportunities and challenges,” the report said.
Related: Evolving Life Sciences/Healthcare Sector Busier Than Ever for Recruiters
According to the recent Economist Intelligence report, Healthcare Outlooks 2024, the forecast for healthcare and pharmaceuticals includes an ongoing balancing act between drug price increases and pricing regulations, climate change concerns, digital health and AI disruptions, and concerns relating to an aging population. Healthcare spending is expected to overtake inflation, finally recovering from the strains of the COVID-19 pandemic.
However, Signium explains that resources will remain constrained in many countries as leaders attempt to bring down fiscal deficits and public debt levels.
Just Released: 2024 Corporate Culture Report
As leaders recognize the critical role of culture in organizational success, building sustainable cultural change for engagement, performance, and growth is now essential. Emphasizing psychological safety allows employees to express ideas, take risks, and voice concerns, driving innovation and engagement.
Hunt Scanlon Media’s 2024 Corporate Culture Report shows how a strong, cohesive culture transforms organizations. By prioritizing cultural synergies and shared values, companies can attract and retain top talent while fostering innovation. Download now!
The report notes that a few of the predictions for the remainder of 2024 include:
- Healthcare spending will rise by 6.1 percent in U.S.-dollar terms and by 1.1 percent in real terms.
- Pharmaceutical spending will rise by 6.5 percent in dollar terms as drug prices continue to rise – despite efforts to regulate them.
- According to U.S. census data, the number of people celebrating their 65th birthday in the U.S. will peak in 2024. The World Health Organization (WHO) predicts that in 2024, the population of individuals aged over 65 years will officially outnumber those under the age of 15 in the WHO European Regions.
- Life expectancy has increased by about 10 years, but life quality has only been extended by approximately three years. This increases demands on drug production and pharmaceutical innovations.
- The healthcare sector is expected to set aside more than 10 percent of its budget, up from about five percent in 2022, to further AI and machine learning.
Hunt Scanlon Media spoke to Signium partners in three significant economies to find out how these changes are both presenting possibilities and placing pressure on the executive environments in life sciences in Italy, the U.S., and Japan. To read more click here!
Related: Leadership Void: Change Agents Sought for Life Sciences Sector
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
